Search Results for keywords:"DEA notice"

The Drug Enforcement Administration (DEA) has decided to revoke Joely Keen's DEA registration because she is no longer authorized to handle controlled substances in Texas. Her licenses to practice as an advanced practice registered nurse (APRN) and registered nurse in Texas have been revoked, and she lacks a necessary prescriptive authority agreement with a supervising physician. Without these, she cannot legally prescribe or dispense controlled substances, resulting in the loss of her DEA registration. The order becomes effective on April 28, 2025.

Noramco Inc has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances, including synthetic versions of Marihuana Extract, Marihuana, and Tetrahydrocannabinols. The company intends to produce these substances as active pharmaceutical ingredients and reference standards for their customers. Interested parties are invited to submit comments, objections, or a request for a hearing regarding this application by April 6, 2021. Written comments should be sent to the DEA's Federal Register Representative in Springfield, Virginia.

Mylan Pharmaceuticals Inc. has submitted an application to be recognized as an importer of controlled substances. The Drug Enforcement Administration (DEA), a part of the Justice Department, is providing notice of this application. Interested parties, such as other registered manufacturers or applicants, have the opportunity to submit written comments, objections, or requests for a hearing on this application by March 8, 2021. Comments and hearing requests should be sent to the DEA at their Springfield, Virginia address.